clinicalstage

RadioMedix Debuts Proprietary bench top Pb Generator to Support Targeted Alpha Therapy Development

New bench top ²¹²Pb generator to expand clinical-grade isotope supply for targeted alpha therapy research and development June 12, 2025…

6 months ago

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

June 10, 2025 13:33 ET  | Source: MiNK Therapeutics NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:…

6 months ago

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

June 06, 2025 16:01 ET  | Source: Keros Therapeutics, Inc. LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics,…

6 months ago

RESTEM to Present Phase 2/3 IIMPACT Trial Design in Idiopathic Inflammatory Myopathy at EULAR 2025 Congress

June 06, 2025 16:07 ET  | Source: Restem MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology…

6 months ago

Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

June 05, 2025 16:58 ET  | Source: Boundless Bio, Inc. SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Boundless Bio…

6 months ago

ImPact Biotech Announces Treatment of First Patient in Phase 1 Clinical Trial of Padeliporfin VTP in Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma (PDAC)

June 05, 2025 16:31 ET  | Source: ImPact Biotech –  Previously inoperable patient converted to eligible for resection, underwent pancreaticoduodenectomy,…

6 months ago

Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)

LEHI, Utah, June 4, 2025 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies inspired by genetic resilience, today…

6 months ago

Addex Convenes Annual General Meeting 2025

June 03, 2025 01:00 ET  | Source: Addex Therapeutics Geneva, Switzerland, June 3, 2025 - Addex Therapeutics (SIX: ADXN and…

6 months ago

Aravax Appoints Louise Peacock as Chief Regulatory and Quality Officer as it Prepares for Phase 3 Development

June 02, 2025 04:00 ET  | Source: Aravax MELBOURNE, Australia and OXFORD, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) --…

6 months ago

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

Treatment with casdatifan, a HIF-2a inhibitor, plus cabozantinib, a tyrosine kinase inhibitor, showed a confirmed overall response rate (ORR) of…

6 months ago